Alchemedicine Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10.2M
- Investors
-
8
Alchemedicine General Information
Description
Provider of drug discovery services intended to treat diseases with unmet medical needs. The company's services actively work to create new drugs even in areas and diseases where drug discovery is seemingly difficult, enabling clients to deliver drugs that are useful to patients as soon as possible.
Contact Information
Website
www.alchemedicine.comCorporate Office
- 4th Floor, Tsukuba Center Building, 1-10-1 Azuma
- Tsukuba City, 305-0031
- Japan
Corporate Office
- 4th Floor, Tsukuba Center Building, 1-10-1 Azuma
- Tsukuba City, 305-0031
- Japan
Alchemedicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 18-Dec-2022 | $10.2M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series C) | 16-Feb-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 18-Oct-2019 | $2.02M | $2.4M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 14-Jun-2019 | $385K | $385K | Completed | Pre-Clinical Trials |
Alchemedicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Shares | ||||||||
| C Shares | ||||||||
| B Shares | 39,544 | $39.9 | $39.9 | 1x | $39.9 | 17.48% | ||
| A Shares | 15,000 | $20.31 | $20.31 | 1x | $20.31 | 6.63% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Alchemedicine Patents
Alchemedicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026014456-A1 | Compound, complement factor d inhibitor, and pharmaceutical composition | Pending | 10-Jul-2024 | ||
| WO-2024101440-A1 | Compound, endothelin a receptor antagonist, angiotensin ii type 1 receptor antagonist, and pharmaceutical composition | Inactive | 11-Nov-2022 | ||
| JP-2025183466-A | Compound, endothelin receptor antagonist, angiotensin ii type 1 receptor antagonist, and pharmaceutical composition | Pending | 11-Nov-2022 | ||
| AU-2023257780-A1 | Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug | Pending | 22-Apr-2022 | ||
| US-20250084036-A1 | Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug | Pending | 22-Apr-2022 | C07D213/56 |
Alchemedicine Signals
Alchemedicine Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mizuho Capital | Venture Capital | Minority | ||
| Beyond Next Ventures | Venture Capital | Minority | ||
| Enjoyor Investment | Corporate Venture Capital | Minority | ||
| Jafco | Venture Capital | Minority | ||
| Joyo Capital Partners | Corporate Venture Capital | Minority |
Alchemedicine FAQs
-
When was Alchemedicine founded?
Alchemedicine was founded in 2019.
-
Where is Alchemedicine headquartered?
Alchemedicine is headquartered in Tsukuba City, Japan.
-
What is the size of Alchemedicine?
Alchemedicine has 3 total employees.
-
What industry is Alchemedicine in?
Alchemedicine’s primary industry is Drug Discovery.
-
Is Alchemedicine a private or public company?
Alchemedicine is a Private company.
-
What is the current valuation of Alchemedicine?
The current valuation of Alchemedicine is .
-
What is Alchemedicine’s current revenue?
The current revenue for Alchemedicine is .
-
How much funding has Alchemedicine raised over time?
Alchemedicine has raised $19.8M.
-
Who are Alchemedicine’s investors?
Mizuho Capital, Beyond Next Ventures, Enjoyor Investment, Jafco, and Joyo Capital Partners are 5 of 8 investors who have invested in Alchemedicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process